Znanstveni rad - Ostalo
PCSK9 inhibitors in clinical practice: Expectations and reality
Atherosclerosis (Amsterdam), 270 (2018); 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001


Citirajte ovaj rad

Reiner, Ž. (2018). PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis (Amsterdam), 270., 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations and reality." Atherosclerosis (Amsterdam), vol. 270, 2018, str. 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001

Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations and reality." Atherosclerosis (Amsterdam) 270 (2018): 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001

Reiner, Ž. (2018) 'PCSK9 inhibitors in clinical practice: Expectations and reality', Atherosclerosis (Amsterdam), 270, str. 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Reiner Ž. PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis (Amsterdam) [Internet]. 2018. [pristupljeno 12.07.2024.];270:187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Ž. Reiner, "PCSK9 inhibitors in clinical practice: Expectations and reality", Atherosclerosis (Amsterdam), vol. 270, str. 187-188, 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:226642. [Citirano: 12.07.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.